SB2540 extends and continues Mississippi’s Health Care Industry Zone Act and the related tax incentives that support qualifying health care and life-science projects. The bill pushes the act’s repeal date from July 1, 2025 to July 1, 2026 and similarly extends the sunset on the associated sales tax exemption for construction materials, machinery, and equipment used in health care industry facilities. It also brings forward the underlying zone-act sections for possible amendment, but the substantive eligibility rules remain largely the same: qualifying facilities generally include pharmaceutical, biotechnology, medical equipment, diagnostic imaging, and related research, manufacturing, distribution, and laboratory operations, subject to job-creation and capital-investment thresholds.
The bill preserves the package of incentives available to certified qualified businesses in a health care industry zone. Those incentives include accelerated state income tax depreciation, a sales tax exemption, a fee-in-lieu of ad valorem taxes, and an ad valorem tax exemption. It also extends the dates by which local governments may grant the ad valorem exemption and fee-in-lieu arrangements for these facilities, while removing the reverter language that would otherwise have caused those provisions to lapse. The bill continues to exclude medical cannabis establishments from these benefits.
In addition to the health care zone provisions, SB2540 updates the general ad valorem and sales tax statutes to keep the health care industry facility exemption in place through June 30, 2026. The local tax provisions in Sections 27-31-101 and 27-31-104 are revised so counties and municipalities may continue to grant property-tax exemptions and fee-in-lieu agreements for qualifying health care projects, and Section 27-65-101 is amended so the sales tax exemption for construction and equipment purchases tied to health care industry facilities remains available for another year. The practical effect is to preserve Mississippi’s targeted economic-development incentives for health care-related capital projects and the local governments that negotiate them.
The overall sentiment reflected in the bill’s history is strongly favorable. The Senate passed the bill overwhelmingly, 50-1, indicating broad support for extending the program. No committee transcript was provided, but the vote suggests the measure was viewed as a routine continuation of an existing economic-development policy rather than a controversial new initiative.
The main point of contention is the policy choice to continue tax incentives for a narrow class of projects, which reduces tax revenue for state and local governments while benefiting qualifying private facilities. The bill also maintains categorical exclusions for medical cannabis establishments, and it preserves the requirement that projects meet job and investment thresholds and, in some cases, MDA criteria or certificate-of-need-related conditions. Those eligibility limits, along with the extension of local tax abatements, are the key features likely to matter most to developers, counties, municipalities, school districts, and competing industries.
SB2540 amends Mississippi Code Sections 57-117-11, 27-31-101, 27-31-104, and 27-65-101 to extend the life of the Mississippi Health Care Industry Zone Act and its associated tax incentives through June 30, 2026. It preserves the statutory framework authorizing state income tax depreciation benefits, sales tax exemptions, ad valorem tax exemptions, and fee-in-lieu agreements for certified health care industry facilities, while removing sunset/reverter language that would otherwise terminate those provisions. The bill affects counties, municipalities, school districts, the Mississippi Development Authority, and qualifying health care and life-science businesses by continuing the availability of these economic-development incentives for another year.
The bill appears to have broad bipartisan or at least near-unanimous support in the Senate, passing 50-1. That vote suggests the chamber viewed the extension as a continuation of an established incentive program rather than a major policy dispute. With no committee transcript available, the public record here shows little overt opposition, and the overall tone is favorable toward retaining the health care industry zone incentives.
The principal policy tension is between economic development and tax expenditure: supporters favor extending incentives to attract or retain health care and biomedical investment, while critics could question the loss of state and local tax revenue and the use of targeted abatements. Another notable issue is the bill’s continued exclusion of medical cannabis establishments from eligibility, which narrows the class of beneficiaries and reflects a policy boundary around the incentive program. The bill also preserves MDA certification and job/capital thresholds, which can be a point of contention for businesses that do not meet the criteria or for local governments balancing development goals against school and county revenue needs.